[13C]-pantoprazole breath test to predict CYP2C19 phenotype and efficacy of a proton pump inhibitor, lansoprazole

Alimentary Pharmacology and Therapeutics

Volumn 30, Issue 3, 2009, Pages 294-300

  Furuta, T ^a   Kodaira, C ^a   Nishino, M ^a   Yamade, M ^a   Sugimoto, M ^a   Ikuma, M ^a   Hishida, A ^a   Watanabe, H ^a   Umemura, K ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBON 13; CARBON DIOXIDE; CYTOCHROME P450 2C19; LANSOPRAZOLE; PANTOPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIULCER AGENT; CYP2C19 PROTEIN, HUMAN; DIAGNOSTIC AGENT; ENZYME INHIBITOR; PROTON PUMP INHIBITOR; UNSPECIFIC MONOOXYGENASE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREATH ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GASTRIC PH MONITORING; GENE FREQUENCY; HUMAN; HUMAN EXPERIMENT; JAPANESE; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ADOLESCENT; AGED; METABOLISM; MIDDLE AGED;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-ULCER AGENTS; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; BREATH TESTS; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTON PUMP INHIBITORS; YOUNG ADULT;

EID: 67650407494     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04044.x     Document Type: Article

References (18)

1. Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol 2008 64 : 935 51.
2. Meyer UA. Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Yale J Biol Med 1996 69 : 203 9.
3. Ieiri I, Mamiya K, Urae A, et al. Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese. Br J Clin Pharmacol 1997 43 : 441 5.
4. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2004 5 : 181 202. (Pubitemid 38351277)
5. Furuta T, Sugimoto M, Shirai N, Ishizaki T. CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor. Pharmacogenomics 2007 8 : 1199 210.
6. Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998 129 : 1027 30.
7. Furuta T, Shirai N, Watanabe F, et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 2002 72 : 453 60.
8. Kawamura M, Ohara S, Koike T, et al. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 2003 17 : 965 73.
9. Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007 81 : 521 8.
10. Furuta T, Ohashi K, Kosuge K, et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999 65 : 552 61.
11. Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 2001 70 : 484 92.
12. Furuta T, Shirai N, Takashima M, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001 69 : 158 68.
13. Tanaka M, Ohkubo T, Otani K, et al. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4′-hydroxylation phenotype and genotype. Clin Pharmacol Ther 1997 62 : 619 28.
14. Desta Z, Modak A, Nguyen PD, et al. Rapid identification of the hepatic cytochrome P450 (CYP) 2C19 activity using a novel and noninvasive [13C]-pantoprazole breath test. J Pharmacol Exp Ther 2009 329 : 297 305.
15. Furuta T, Sagehashi Y, Shirai N, et al. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H. pylori Infection. Clin Gastroenterol Hepatol 2005 3 : 564 73.
16. Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 2006 79 : 103 13.
17. Klotz U. Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 2006 44 : 297 302. (Pubitemid 44043771)
18. Kato M, Asaka M, Ohara S, Toyota T. Clinical studies of 13C-urea breath test in Japan. J Gastroenterol 1998 33 (Suppl 10 36 9.